CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
ARD-101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05121441
NCT05121441Phase 2Completed
CompareCT.gov

A Phase 2, Placebo-Controlled, Randomized, Blinded Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ARD-101 in Adults With Obesity

Aardvark Therapeutics, Inc.·interventional·Posted Nov 16, 2021·Updated Jan 22, 2025

In Brief

A Phase 2 clinical trial evaluating ARD-101 and Placebo for Obesity. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in obese subjects with a body mass index (BMI) of 30-45 kg/m2.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsUniversity of California, San Diego

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedNov 16, 2021
Enrollment StartNov 15, 2021
Primary CompletionNov 9, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 4.6 years ago

Interventions

ARD-101drug

Twice daily, oral administration

Placebodrug

Twice daily, oral administration